Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

C. Gambacorti-Passerini, MD, H. Kantarjian, MD, T. Bruemmendorf, MD, G. Martinelli, MD, M. Baccarani, MD, T. Fischer, MD, E.M. Pogliani, MD, B. Hewes, MD, A.D.G. Volkert, MD, N. Bardy-Bouxin, MD, J. Cortes, MD

Blood (2007) 110 (11): 473.

https://doi.org/10.1182/blood.V110.11.473.473

Published: 2007

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

J. Cortes, MD, T. Bruemmendorf, MD, H. Kantarjian, MD, J. Khoury, MD, G. Rosti, MD, T. Fischer, MD, L. Tornaghi, MD, B. Hewes, MD, E.C. Martin, MD, C. Gambacorti-Passerini, MD

Blood (2007) 110 (11): 733.

https://doi.org/10.1182/blood.V110.11.733.733

Published: 2007

Journal Articles

Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

F. Heidel, MD, J. Cortes, MD, F. Ruecker, MD, M. Kaufmann, MD, W. Aulitzky, MD, L. Letvak, MD, T. Kindler, MD, C. Huber, MD, H. Dohner, MD, H. Kantarjian, MD, T. Fischer, MD

Blood (2005) 106 (11): 1853.

https://doi.org/10.1182/blood.V106.11.1853.1853

Published: 2005

Journal Articles

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

M. Gorre, H. Kantarjian, I. Jilani, J. Cortes, A. Salvado, P. Rae, L. Alland, M. Dugan, O. Ottmann, K. Bhalla, F. Giles, M. Albitar

Blood (2005) 106 (11): 2001.

https://doi.org/10.1182/blood.V106.11.2001.2001

Published: 2005

Journal Articles

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

I. Jilani, H. Kantarjian, H. Faraji, M. Gorre, J. Cortes, O. Ottmann, K. Bhalla, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2006.

https://doi.org/10.1182/blood.V106.11.2006.2006

Published: 2005

Journal Articles

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2007.

https://doi.org/10.1182/blood.V106.11.2007.2007

Published: 2005

Journal Articles

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

Francois Guilhot, J.F. Apperley, N. Shah, D.W. Kim, A. Grigg, S. Cheng, M. Iyer, J. Cortes

Blood (2005) 106 (11): 39.

https://doi.org/10.1182/blood.V106.11.39.39

Published: 2005

Journal Articles

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Charles L. Sawyers, H. Kantarjian, N. Shah, J. Cortes, R. Paquette, N. Donato, J. Nicoll, E. Bleickardt, T.-T. Chen, M. Talpaz

Blood (2005) 106 (11): 38.

https://doi.org/10.1182/blood.V106.11.38.38

Published: 2005

Journal Articles

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, F. Giles, MD, J. Cortes, MD, D. Thomas, MD, F. Ravandi, MD, G. Garcia-Manero, MD, M. Andreeff, MD, S. Lerner, MS, H. Kantarjian, MD, M. Keating, MD

Blood (2005) 106 (11): 719.

https://doi.org/10.1182/blood.V106.11.719.719

Published: 2005

Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS

Blood (2005) 106 (11): 5018.

https://doi.org/10.1182/blood.V106.11.5018.5018

Published: 2005

Journal Articles

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, F. Giles, J. Cortes, S. Verstovsek, S. O’Brien, M. Keating, M. Albitar

Blood (2005) 106 (11): 2593.

https://doi.org/10.1182/blood.V106.11.2593.2593

Published: 2005

Journal Articles

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis Giles, MD, H. Kantarjian, MD, B. Wassmann, J. Cortes, MD, S. O’Brien, MD, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, MD, O. Ottmann

Blood (2004) 104 (11): 22.

https://doi.org/10.1182/blood.V104.11.22.22

Published: 2004

Journal Articles

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia

J Cortes, SM O'Brien, S Pierce, MJ Keating, EJ Freireich, HM Kantarjian

Blood (1995) 86 (6): 2091–2097.

https://doi.org/10.1182/blood.V86.6.2091.bloodjournal8662091

Published: 1995

NARROW

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only